Učinak terapije hormonom rasta u djece s Prader-Willijevim sindromom - prva vlastita iskustva by Gordana Stipančić et al.
Acta Clin Croat 2018; 57:744-755 Professional Paper
doi: 10.20471/acc.2018.57.04.17
Acta Clin Croat, Vol. 57, No. 4, 2018744
EFFECT OF GROWTH HORMONE THERAPY 
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SUMMARY – Prader-Willi syndrome (PWS) is the most common cause of morbid obesity in 
childhood. It is the consequence of the lack of expression of genes on the paternally inherited 15q11.2-
q13 region. Hyperphagia, obesity, short stature, psychomotor retardation and deterioration of behavior 
predominate in clinical presentation. Recombinant human growth hormone (rhGH) therapy, along 
with restriction of caloric intake, has become the mainstay in the management of PWS patients. 
 Anthropometric parameters (height, body mass index (BMI)), therapy eff ect on carbohydrate and 
lipid metabolism, and occurrence of side eff ects were monitored in four children with PWS treated 
with rhGH for ³2 years at doses of up to 1 mg/m2/day. During the follow-up, the height standard 
deviation score (SDS) increased in comparison with baseline values, and after ³2 years of treatment 
with rhGH it was within the reference range for the general children population. BMI SDS decreased 
after the fi rst year of treatment, but thereafter increased again; still, the level of BMI SDS was much 
better in comparison with most children with PWS of the same age and gender. RhGH therapy had 
no negative eff ect on glucose and lipid metabolism, nor caused any other adverse eff ect. Th erapy 
 including a customized diet for PWS, along with rhGH therapy, provided a satisfactory growth rate 
and prevented development of morbid obesity without side eff ects. Th is treatment approach would 
ensure transition of a greater number of PWS patients into adult care, where the multidisciplinary 
approach in care should be continued.
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Introduction
Prader-Willi syndrome (PWS, OMIM 176279) is 
the most common cause of severe obesity in early 
childhood, and was fi rst described by A. Prader, A. 
Lambhart and H. Willi in 19561. PWS is the result of 
a genetic disorder caused by the lack of expression of 
genes on the paternally inherited 15q11.2-q13 region2.
Th e basic clinical characteristics include reduced 
muscle tone, which starts during intrauterine develop-
ment and causes decreased fetal movements. In new-
borns and infants, hypotonia disrupts feeding and 
weight gain. However, feeding diffi  culties cease soon 
and excessive food intake develops, leading to morbid 
obesity. Obesity is accompanied by changes in the 
body composition, with increased body fat tissue and 
concomitant reduced amount of muscle mass. Despite 
obesity, these children do not grow properly and stay 
short; sexual development is absent and psychomotor 
development is retarded as well3. Most PWS patients 
have mild intellectual retardation with an average 
 intelligence quotient (IQ) of 61, within a range of 
40-1034.
Individuals with PWS have a characteristic dys-
morphic phenotype, i.e. narrow bifrontal diameter, 
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short eye slits and thin upper lip. Small hands and feet 
are predominant; hair, eyes and skin are often lighter 
than in other family members5.
DNA methylation test will determine the critical 
genetic region inherited exclusively from the mother 
and thereby confi rm the diagnosis in 99% of patients. 
Th ere are three main genetic mechanisms responsible 
for the development of PWS. In 65%-75% of cases, 
the cause is a deletion of the father’s chromosome in 
the 15q11-q13 region, 20%-30% of patients will have 
maternal uniparental disomy of chromosome 15, and a 
defect in the region that controls the imprinting pro-
cess is responsible in only 1%-3% of patients6,7. Ge-
netic analysis is essential for confi rmation of the dis-
ease in all patients, especially in those who have not yet 
developed clinical characteristics of the disease or dis-
play atypical features. Early confi rmation of the diag-
nosis, usually during the workup for neonatal hypoto-
nia, is an opportunity to implement all treatment op-
tions available as early as possible8.
Th e incidence of the disease is diffi  cult to deter-
mine, however, based on data from the European 
countries it ranges from 1:10,000 to 1: 30,000 live 
births, with a prevalence in the general population of 
1:50,000. Today, there are 350,000-400,000 aff ected 
individuals worldwide. An increase in the incidence is 
expected, as uniparental disomy is more common in 
older mothers. Th e mortality rate among aff ected indi-
viduals at the age of 6-56 years is 3% per year, as op-
posed to 0.14% in the general population9,10.
Overweight in otherwise healthy children during 
the growth period results in normal fi nal height, fre-
quently above the genetic potential and midparental 
height. Despite being overweight, children with PWS 
lag behind in growth and end up short. Consequently, 
growth hormone (GH) secretion is decreased and in-
sulin-like growth factor (IGF 1) ranges are within the 
normal limits. Th e mean fi nal height is below midpa-
rental height; in males, it amounts to 161.6±8.1 cm 
(-2.4 standard deviation score, SDS) and in females to 
150.2±5.5 cm (-2.5 SDS)11. Short stature despite obe-
sity, body composition with predomination of fat tis-
sue, low IGF 1 levels, poor response of GH to pharma-
cological GH stimulation tests and decreased sponta-
neous GH secretion during 24 h clearly indicate GH 
defi ciency12. As a GH defi cit is present in 80% of those 
aff ected, testing before recombinant human growth 
hormone (rhGH) therapy is not required and only 
IGF 1 levels need to be evaluated, serving as useful 
indicators of the patient compliance to therapy and 
his/her GH sensitivity7,12. Besides GH defi ciency, ab-
sence of the pubertal growth spurt due to hypogonad-
ism or hypothyroidism can also contribute to the de-
velopment of short stature.
In the late 1990s, randomized controlled studies 
confi rmed the positive eff ect of rhGH therapy on the 
course of PWS. Th is therapy accelerated growth and 
improved fi nal height, increased the amount of muscle 
mass and muscle tone, and thereby muscular strength, 
and the capacity for physical activity. Th e portion of fat 
tissue was decreased and respiratory function im-
proved, while positive behavioral changes were also 
noted13,14. Based on this, the US Food and Drug Ad-
ministration (FDA) approved the use of rhGH in 
PWS children with short stature in the USA in 2000, 
and the European Medicines Agency (EMA) ap-
proved its application, indenpendently of height, in 
Europe in 2002, with the intention to improve body 
composition. Th ereby, rhGH therapy has become a 
standard in the management of PWS children in de-
veloped countries.
Hypothalamic dysfunction not only causes pitu-
itary hormone defi ciency, but also other features of 
PWS such as unstable temperature, high threshold for 
pain, and inability to induce vomiting. Th ese features 
make it more diffi  cult to diagnose acute illnesses. Par-
ticular caution is needed with binge eating, which may 
cause choking, as well as stomach dilatation with ne-
crosis and perforation8.
Two deaths of our PWS patients in adolescence 
were a strong motivation to improve the outcome of 
the disease. Th us, we were the fi rst in Croatia to apply 
rhGH in our patients in 2009. Until now, seven chil-
dren have been included in the treatment, four of 
which have been followed up for ³2 years. By present-
ing the results, we want to draw attention of a wider 
medical public in Croatia to the possibilities of such 
treatment for this rare disease.
Patients and Methods
We conducted a retrospective analysis of patient 
histories of four PWS patients, one girl and three boys, 
who were and/or are currently treated with rhGH due 
to PWS. Th e genetic basis of the disease was confi rmed 
in all patients. In the female patient, blood samples 
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from the biological parents were unavailable; therefore, 
the diagnosis was made only by methylation test; in 
the other three patients, molecular testing confi rmed 
microdeletion or uniparental disomy. Additionally, 
each patient was karyotyped from a sample of periph-
eral blood.
Immediately before rhGH therapy had been intro-
duced, as well as during the follow-up, anthropometric 
measurements were performed in all patients; height 
was measured by the Harpenden stadiometer and body 
weight by calibrated scales with a lever. All initially 
measured height and body mass index (BMI) values in 
kg/m2 (according to the formula: body weight in kg 
divided by height in m2), as well as those measured 
during the follow-up were compared with the stan-
dardized National Center for Health Statistics 
(NCHS) growth curve for the general population of 
children15. In order to unite the values for both gen-
ders, we expressed the z-values (SDS) for height and 
BMI according to the NCHS curve at baseline, after 
12 months, and at the last check-up.
At the beginning of treatment, three children were 
in prepuberty, the girl with breast Tanner stage <2, and 
the boys with testicles <4 mL volume. One boy was in 
early spontaneous puberty, with testicles 6 mL by 
Prader and genital development stage 2 by Tanner and 
Whitehouse16.
Th e doses of rhGH during the treatment were up 
to 1 mg/m2, i.e. 0.035 mg/kg/day (Genotropin; Pfi zer 
Inc., Zagreb, Croatia), and were gradually increased 
during the fi rst 6-9 months, along with evaluation of 
IGF 1 levels. From that point on, the doses of rhGH 
were adjusted every 6 months according to the body 
surface area and IGF 1 levels.
Fasting blood glucose, insulin level, lipid profi le, 
free thyroxine (fT4), thyroid-stimulating hormone 
(TSH) and adrenocorticotropic hormone (ACTH) 
were determined using classic techniques at the begin-
ning of treatment and every 6-12 months thereafter. A 
low-dose ACTH test was performed at the beginning 
of treatment in order to evaluate adrenal function.
Th e homeostatic model assessment of insulin resis-
tance (HOMA-IR) index was calculated using the 
classic formula: product of fasting blood glucose 
(mmol/L) and fasting insulin level (mIU/mL) divided 
by 22.5.
Before therapy introduction and in the fi rst year of 
treatment, each child underwent all-night polysomno-
graphic recording and had his/her apnea/hypopnea 
index (AHI) determined. Before introducing rhGH 
therapy, as well as once annually or as needed thereaf-
ter, radiologic evaluation of the spine was performed to 
see progression of the possibly present scoliosis. Oto-
rhinolaryngoscopic examination evaluated the tonsils 
and adenoids and indicated adenotonsillectomy when 
necessary.
Th e aim of the research was to investigate the eff ect 
of rhGH on anthropometric parameters, height and 
BMI, and evaluate the safety of therapy by observing 
IGF 1 levels, glucose homeostasis and lipid profi le. 
Levels and secretion of pituitary and peripheral endo-
crine hormones, as well as the occurrence of adverse 
eff ects were also monitored.
Before therapy introduction, the parents signed an 
informed consent form, which included information 
on the benefi ts and possible risks of the treatment.
Results
Starting in 2009, we have been treating four PWS 
patients with rhGH for ³24 (range 36 to 96) months. 
Th eir most relevant clinical characteristics are shown 
in Table 1. All children were term born; in two of 
them, delivery was performed by cesarean section due 
to breech position and threatening asphyxia. In two 
children, birth weight and length were within the ref-
erence range for gestational age, and the other two 
were small for gestational age. In all children, hypoto-
nia was recorded immediately after birth, leading to 
diagnostic workup and confi rmation of the diagnosis 
of PWS in three children in the fi rst year of life. In the 
fourth child, the oldest in the group, diagnostic work-
up was done at the age of 4, when it became available 
in our country. All children were included in a habili-
tation program due to hypotonia and motor retarda-
tion. Th ree children have cognitive development retar-
dation with IQ between 57 and 71, and the fourth 
child has IQ 83 and attends second grade of the regu-
lar elementary education program.
All patients had normal karyotypes. In two pa-
tients, PWS was caused by deletion of the 15q11-q13 
region, and in one patient by maternal uniparental di-
somy of the same region. In the female patient, the 
diagnosis was made only by methylation test, confi rm-
ing the lack of expression of the father's allele in the 
15q11-q13 region because blood samples from the 
biological parents were unavailable.
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Initial problems with feeding were present in two 
children. Th e period of hyperphagia began between 
the second and fourth year of life in all children. Th e 
parents of the children that were diagnosed as infants 
were given instructions about the dietary regimen re-
quired.
RhGH therapy started at the age between 2.8 and 
10.5 years. Th ree children were in prepuberty and one 
boy in spontaneous early puberty, but after two years 
further progression of puberty was lacking. In one boy, 
spontaneous early puberty began during treatment at 
the age of 9.5, and is still progressing. At the point of 
introduction of rhGH therapy, the patient height SDS 
was between -0.62 and -2.5. In the children that were 
not of short stature, previous follow up showed growth 
retardation. Th e three children whose parents' heights 
were known had a height SDS lower by 1.8-3.2 than 
the midparental height (Table 1).
Th e growth hormone stimulation test was not per-
formed before the introduction of rhGH; only IGF 1 
was measured for the purpose of further follow up. Af-
ter 3 to 8 years of treatment, there was an increase in 
height SDS between 0.45 and 1.12, and therapy is still 
ongoing in three children. After 8 years of treatment, 
one boy attained his fi nal height of 172.7 cm, 44.3c, 
-0.14 SDS, which was still below his midparental 
height (185 cm, 94 c, 1.55 SDS). He started rhGH 
therapy relatively late, at the age of 10.5 years, and 
he also developed early spontaneous puberty (Fig. 1, 
Table 1).
At initiation of rhGH therapy, two patients had 
BMI in the range of severe obesity (BMI >99 c), one 
patient's BMI was in the range of overweight (BMI 
>85c but <95c), and one child had BMI of <85c for age 
and gender, which is consistent with normal weight. 
After the fi rst year of treatment, there was a signifi cant 
BMI decrease in all children, followed by its gradual 
increase. However, at this point of treatment, which 
has been administered for 3 and 8 years, BMI is still 
better in three children; in the fourth child, there has 
been a BMI SDS increase by 0.1 after 6.5 years of 
treatment, but the absolute BMI value is in the 85 per-
Table 1. Clinical and anthropometric characteristics of children with Prader-Willi syndrome treated with recombinant 
human growth hormone
Patient 1 2 3 4
Age at therapy initiation (yrs) 10.5 7.2 2.8 5.5
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centile. Th e young man who has attained his fi nal 
height has BMI of 26.5 kg/m2
, 
95.7 c, 1.7 SDS (Fig. 1, 
Table 1).
In all children, the planned initial dose of rhGH 
was 1 mg/m2, i.e. 35 μg/kg body weight. Th e dose was 
gradually increased during the fi rst few months of 
treatment and adjusted with IGF 1 levels, which were 
kept between 1 and 2 SD for chronologic age. Th e 
doses of rhGH were in the range of 20-35 μg/kg body 
weight.
Table 2 shows PWS children comorbidities and 
their metabolic status through parameters measured 
during rhGH therapy. Breathing problems during 
sleep expressed by the apnea/hypopnea index during 
all-night polysomnographic recording before treat-
ment initiation were above 1 in three of four children, 
and the follow-up apnea/hypopnea index 3-6 months 
after treatment initiation was lower than the initial 
one in all children or <1. In two children, adenotonsil-
lectomy was performed before therapy introduction. 
Two children developed hypothyroidism during rhGH 
therapy and are now on replacement therapy with le-
vothyroxine. A low-dose ACTH test did not confi rm 
secondary adrenal insuffi  ciency in any of the children. 
All male children had unilateral or bilateral unde-
scended testes requiring orchidopexy. At treatment 
initiation, as well as during the follow up, insulin, 
blood glucose and HOMA-IR were within the nor-
mal limits for patient age and pubertal stage of devel-
opment. None of the children developed diabetes dur-
ing the follow up. At the beginning of treatment, ele-
vated low-density lipoprotein (LDL) cholesterol was 
Fig. 1. Growth parameters (height SDS, BMI SDS) in PWS patients during RhGH therapy.
SDS = standard deviation score; BMI = body mass index; PWS = Prader-Willi syndrome; RhGH = recombinant human growth hormone
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found in two children, but improved during therapy. In 
the other two patients, LDL cholesterol was within 
the normal range during the course of treatment. Dur-
ing rhGH therapy, no serious side eff ects (malignant 
disease, pseudotumor cerebri, slipped capital femoral 
epiphysis, sleep apnea disorder) and no fatal outcomes 
were recorded.
Discussion
In our patients, rhGH therapy was confi rmed to 
have a positive eff ect on the growth rate and conse-
quently on the fi nal height and BMI achieved, thereby 
changing the natural course of the anthropometric 
features in PWS. Despite the improvement in height, 
the patient who attained his fi nal height did not 
achieve his genetic potential by reaching the midpa-
rental height. It may have been due to the fact that in 
his case, the treatment started relatively late, at the age 
of 10.5 years, and was compromised by early puberty. 
Th e positive eff ect on BMI was the result of both 
height increase with rhGH therapy, as well as early ge-
netic confi rmation of the disease, which was in most of 
our patients performed in the fi rst year of life. Th is en-
abled the families to focus on the importance of an 
appropriate diet for PWS patients, characterized by a 
limited energy intake with a macronutrient ratio in 
which carbohydrates account for 45%, proteins for 
25% and fats for 30% of the daily energy inake17.
Research results showed that rhGH therapy in 
children with PWS lasting for years had a positive ef-
fect on several parameters. Th erapy with rhGH accel-
erated growth and improved and often normalized the 
fi nal height. Th e eff ect on muscle and fat tissue im-
proved body composition, muscle strength, motor de-
velopment and cognitive abilities in infants and 
 children, as well as bone mineral density and lipid 
 profi le18-22. After almost 8 years of rhGH therapy, the 
fi nal height in women increased by 14 cm and in men 
by 17 cm in comparison to untreated patients23. In a 
study by Dutch authors, the amount of muscle tissue 
increased signifi cantly in the fi rst year of treatment 
with rhGH and remained above the baseline for the 
next 7 years. Unfortunately, the portion of fatty tissue 
increased again after a signifi cant fall in the fi rst year 
of therapy. It was explained by the natural course of 
PWS, which cannot be completely altered by rhGH18. 
RhGH therapy administered for several years main-
tains BMI SDS in the reference range for the general 
population, signifi cantly improving it compared to 
that of untreated PWS patients, which is a great suc-
cess for this group of patients18,21. Two of our patients 
were severely obese at treatment initiation, with BMI 
SDS of 2.8 and 3.6 (>99 c), respectively, and 6 and 8 
years of treatment resulted in a fall of BMI SDS to 1.7 
and 1.9, respectively. One child was of normal weight 
before therapy initiation and stayed so after 6.5 years 
of treatment (Table 1, Fig. 1).
With the change in body composition, primarily by 
the increase in muscle mass, a positive eff ect of rhGH 
on muscle strength was also noted, along with the con-
Table 2. Metabolic status and comorbidities in children 
with Prader-Willi syndrome treated with recombinant 
human growth hormone
Patient 1 2 3 4
Hypogonadism RP/+ Ø EP/PA PP
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EP = early puberty; PP = prepuberty; PA = premature adrenarche; 
AHI = apnea/hypopnea index; HOMA-IR = homeostatic model 
assessment of insulin resistance; op = operation; orch = orchido-
pexy; orch R = right orchidopexy; orch B = bilateral orchidopexy
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sequently increased physical activity. RhGH therapy 
signifi cantly reduces the retention of visceral fatty tis-
sue, an eff ect which disappears when therapy is dis-
continued24.
During rhGH therapy, there were also improve-
ments in motor and cognitive development. Results of 
a randomized controlled study indicate that long-term 
rhGH therapy signifi cantly improves verbal abilities, 
as well as visuospatial orientation. IQs were also in-
creased, but not at the level of signifi cance25. Th e 
mechanism that contributes to such a positive out-
come lies in the action (eff ect) of rhGH on brain de-
velopment, as indicated by an increase in head circum-
ference. It is clear that greater motor activity of the 
child owing to better muscular tone and strength con-
tributes to the education process and thus aids cogni-
tive development22,26,27. Th e role of rhGH and IGF in 
the development of cognitive functions requires fur-
ther research. Current data indicate that rhGH thera-
py will not normalize cognitive abilities, but will im-
prove them and thereby reduce the diff erence between 
aff ected children and their healthy peers28.
Th erefore, the goal of rhGH therapy in children 
with PWS is diff erent from that in other states of hy-
posomatotropism. Its aim is not only to increase the 
growth rate and fi nal height, but also to improve body 
composition and increase body activity, thereby ulti-
mately contributing to obesity prevention.
Soon after the introduction of rhGH therapy in 
children with PWS, sudden death outcomes were re-
ported, occurring most frequently in the early stages of 
treatment29. Investigating the causes of death in 64 in-
dividuals with PWS, the French authors stated that 
44% of the patients had been treated with rhGH at the 
time of death. Regardless of whether they were treated 
with rhGH or not, the most common cause of death 
was a respiratory system disorder, respiratory insuffi  -
ciency or infection. Seventy-fi ve percent of death out-
comes occurred in the fi rst 9 months of treatment30. 
Several possible mechanisms of sudden death during 
treatment were considered. According to the fi rst, 
rhGH promotes hypertrophy of tonsillar and sur-
rounding soft tissue, causing obstructive sleep apnea. 
According to the second, an increase in the basal met-
abolic rate causes higher oxygen requirements that 
cannot be met, whereas the third mechanism involves 
increased hydration due to water retention, which can 
result in heart volume overload31. Of the three theories 
mentioned above, most attention was paid to the one 
pointing to sleep disturbance disorders due to tonsillar 
tissue hypertrophy, which is why otorhinolaryngologic 
examination and polysomnographic recording should 
be performed before rhGH therapy introduction. Pa-
tients with PWS often suff er not only from obstructive 
but also from central sleep apnea. Th e contributing 
factors are obesity, restrictive pulmonary disease due to 
muscular weakness and scoliosis, as well as reduced re-
sponse to hypercapnia and hypoxia during sleep6. 
Studies have confi rmed that high baseline AHI caused 
by both obstructive and central sleep apnea remained 
the same or improved after rhGH therapy introduc-
tion32, primarily owing to a decreased number of cen-
tral sleep apnea episodes33. Recent studies also confi rm 
that after 2 years of rhGH treatment, no signifi cant 
changes in sleep disorders occurred34.
Comparing the size of tonsillar tissue prior to 
rhGH introduction and 4 years later, Berini et al. re-
port an increase in primarily adenoid tissue, which re-
quired cessation of therapy due to breathing disor-
ders35. In healthy children and those with PWS, ade-
notonsillectomy is the procedure of choice in treating 
obstructive sleep apnea. If disturbances are continued 
after the procedure, the use of continous positive air-
way presssure (CPAP) must be considered36.
Breathing disturbances during sleep are character-
istic for PWS and there is no defi nite evidence that 
rhGH therapy introduction increases the risk of such 
events in most patients, but caution and appropriate 
preparation before therapy initiation, and especially 
during the fi rst year of treatment, are needed. For the 
purpose of assessing sleep disorders before the intro-
duction of rhGH therapy, it is necessary to perform 
otorhinolaryngologic examination and to consider the 
necessity of adenotonsillectomy. Polysomnographic 
recording is also required in all patients. Signifi cant 
sleep disorders should be treated prior to the introduc-
tion of rhGH therapy and repeat polysomnographic 
recording is recommended at 3-6 months after rhGH 
therapy introduction12. Two of our patients underwent 
adenotonsillectomy before rhGH therapy initiation. 
Polysomnography determined that the baseline fre-
quency of AHI was not a contraindication for therapy 
introduction, as follow up values  were also good. Dur-
ing the described treatment, neither adverse eff ects nor 
lethal oucomes occurred.
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Sudden death in PWS patients occurs in all age 
groups irrespective of rhGH therapy. In the age group 
up to 5 years, the most common causes are respiratory 
infections, and male children with a higher BMI are 
more vulnerable. In adolescence, as well as in adult-
hood, death outcomes are primarily a consequence of 
obesity-associated complications30,31.
In addition to unresolved obstructive sleep disor-
der, contraindications for the introduction of rhGH 
therapy in children include severe obesity, poorly con-
trolled diabetes, acute malignant disease and psychosis. 
For children, there is no simple determinant for severe 
obesity, such as the one in adults of BMI >40 kg/m2, 
but it is defi ned by BMI above 99th percentile for age 
and gender associated with complications such as sleep 
disorder, carbohydrate metabolism disorders or non-
alcoholic fatty liver disease12. At the time of therapy 
initiation, two of our children had BMI >99 c, but 
without any additional comorbidities.
During rhGH therapy, special importance is given 
to IGF 1 levels because of the potential eff ect on the 
development of sleep disorders and malignancies. Af-
ter 24 months of rhGH treatment, in 72% of PWS 
children the level of IGF 1 was above 2 SD despite the 
fact that the rhGH dose was lower than that used for 
GH defi ciency37. Until now, the increased sensitivity of 
patients to GH has not been clarifi ed, but it is encour-
aging that the IGF 1 ratio and insulin-like growth 
factor-binding protein 3 (IGFBP 3) remain un-
changed, leading to the conclusion that the level of 
bioavailable IGF 1 is the same as in other GH defi -
ciencies7. Additionally, a recent study suggests that the 
level of immunoreactive IGF 1 is not equal to bioac-
tive IGF 1 during rhGH therapy, and that thus im-
munoreactive IGF 1 is not a true marker for titration 
of rhGH doses in PWS patients38. RhGH therapy 
should be carried out with IGF 1 monitoring every 6 
to 12 months to maintain its level between 1-2 SD in 
order to avoid side eff ects12. Th e effi  cacy of a rhGH 
dose of <1 mg/m2/day administered for a longer period 
is not known, but there are indications that the posi-
tive eff ect on body composition gets weaker21. In our 
patients, with IGF 1 level monitoring, the dose of 
rhGH was 20-35 μg/kg body weight.
Th e optimal time to introduce rhGH therapy is not 
defi ned, but experts claim that therapy should be started 
before obesity develops, at around 2 years of age. Ac-
cording to the recommendations, the starting dose is 0.5 
mg/m2/day with gradual increase to 1 mg/m2/day, as 
this dose provides positive eff ect not only on growth but 
also on body composition12. Today, there is enough evi-
dence to support early treatment, so that in some cen-
tres it begins as early as the fi rst months of life. Cur-
rently there are data on the fi nal height achieved by 
children treated with rhGH from infancy10.
Financial constraints in many environments in-
cluding ours, and considerations related to breathing 
disorders that occur more often at an early age, lead to 
very diff erent approaches in relation to patient age at 
therapy initiation. Since this is a presentation of the 
fi rst patients in whom we applied rhGH treatment, 
therapy was introduced between 2.8 and 10.5 years of 
age. Th irty to eighty percent of patients with PWS 
have scoliosis, with hypotonia contributing to it. Sco-
liosis is not a contraindication for the introduction or 
continuation of rhGH therapy. It is recommended that 
orthopedic examination and, if necessary, spine x-ray 
be performed before the therapy is started12. Two of 
our patients had scoliosis at the beginning of treat-
ment. In one of them, the progression of scoliosis re-
quired surgical correction that was successfully per-
formed.
One of the possible adverse eff ects of rhGH is a 
carbohydrate metabolism disorder due to insulin resis-
tance stimulation. Th erefore, during therapy, fasting 
plasma glucose and fasting insulin levels are moni-
tored, as well as the levels of HbA
1c
, and an oral glu-
cose tolerance test is recommended in obese children 
older than 12 years with a positive family history of 
diabetes12. If lipid profi le dysfunction develops in PWS 
patients, it is consistent with the one seen in GH defi -
ciency and includes elevated levels of total and LDL 
cholesterol and triglycerides, accompanied by a de-
creased level of high-density lipoprotein (HDL) cho-
lesterol. RhGH therapy can positively aff ect the levels 
of LDL and HDL cholesterol13. In our patients, there 
were no disorders of carbohydrate metabolism, and 
two children had elevated levels of LDL cholesterol at 
the beginning of treatment. Th ere were no indications 
of a negative eff ect of rhGH on glucose or lipid me-
tabolism parameters. According to other authors as 
well, therapy lasting for up to 8 years did not have 
negative eff ect on carbohydrate and lipid metabolism, 
blood pressure or progression of bone age18.
Due to hypothalamic dysfunction, in patients with 
PWS, central insuffi  ciency of adrenal gland develops, 
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as confi rmed in 14%-60% of patients depending on 
the stimulation test used6,21. We used a low-dose 
ACTH test and did not establish cortisol or ACTH 
defi ciency in our patients.
In all boys, unilateral or bilateral undescended tes-
tes were present, and orchidopexy was performed. 
During therapy, two patients entered puberty sponta-
neously, and one of them had an early onset of puberty. 
In one of them, complete progression of puberty has 
not occurred and hormone replacement therapy will 
be necessary. Individuals with PWS are almost regu-
larly hypogonadal with delayed or incomplete puberty 
and infertility. Unilateral or bilateral cryptorchism is 
present in 80%-90% of boys and surgical treatment is 
required in the fi rst or second year of life7. Hypogo-
nadism is primarily associated with hypothalamic dys-
function, but today there is growing evidence for pri-
mary gonadal damage as well39.
Central hypothyroidism is recorded in approxi-
mately 25% of PWS children. Th ere is a recommenda-
tion to start screening for hypothyroidism by measur-
ing fT4 and TSH from the age of 3 months despite 
negative neonatal screening results, and then continue 
annual check-ups, especially in patients on rhGH 
therapy. In case hypothyroidism develops, levothyrox-
ine therapy is introduced, which was also necessary in 
two of our patients6.
Th e positive eff ect of rhGH therapy applied in 
childhood is refl ected in adulthood as well, even years 
of its cessation after growth has been completed. Th e 
eff ect is visible in lower BMI, as well as better body 
composition and metabolic status40.
Th e role of rhGH therapy in adult PWS patients is 
currently not clearly defi ned. According to diff erent 
studies, GH defi ciency is present in 15%-95% of the 
aff ected, depending on the pharmacological GH stim-
ulation test used and the agreed level of GH that de-
fi nes GH defi ciency. It is therefore mandatory in many 
countries to assess GH secretion before the introduc-
tion of rhGH therapy6,12. In adults, therapeutic dose of 
rhGH for this group of patients is 0.1-0.2 mg/day 
with maintenance of IGF 1 between 0 and 2 SD, as 
well as monitoring of the clinical response and possi-
ble adverse eff ects12. A meta-analysis of 8 studies eval-
uating the eff ect of rhGH on the body composition in 
adults with PWS has reported a reduction of fat tissue 
mass, visceral and subcutaneous fat, and an increase in 
muscle tissue volume. Individuals treated for 12 
months experienced a mild increase in fasting blood 
glucose41.
Conclusion
Until recently, life expectancy in individuals with 
PWS was signifi cantly reduced. Lethal outcomes at 
the end of the second decade od life were common, 
primarily due to obesity-associated complications. A 
signifi cantly earlier detection of the disease by means 
of genetic analysis has enabled the introduction of 
timely changes in the eating habits of those aff ected, 
which, along with rhGH therapy, has prolonged life 
expectancy and improved the quality of life in most 
patients.
Th erapy implemented until now, including a cus-
tomized diet for PWS, as well as rhGH therapy, has not 
only provided a satisfactory growth rate in our patients, 
but also prevented development of morbid obesity, 
without any adverse eff ects. Th is treatment approach 
will ensure transition of a greater number of PWS pa-
tients into adult (internal medicine) care, where a mul-
tidisciplinary approach in the treatment and care of this 
patient population needs to be continued.
References
 1. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, 
Klainwuchs, Kryptorchismus und Oligophrenie nach myato-
nieartigen Zustand im Neugeborenenalter. Schweiz Med 
Wochenschr 1956;6:1260-61. https://doi.org/10.1007/978-3-
642-47669-3_24 (in German)
 2. Nicholls RD, Knepper JL. Genome organization, function, and 
imprinting in Prader-Willi and Angelman syndromes. Annu 
Rev Genomics Hum Genet. 2001;34:917-23. http://dx.doi.
org/10.1146/annurev.genom.2.1.153
 3. Cassidy SB, Driscoll DJ. Parder-Willi syndrome. Eur J Hum 
Genet 2009;17(1):3-13. 
 https://doi.org/10.1038/ejhg.2008.165
 4. Copet P, Jauregi J, Laurier V, Ehlinger V, Arnaud C, Cobo AM, 
et al. Cognitive profi le in large French cohort of adults with 
Prader Willi syndrome: diff erences between genotypes. J Intel-
lect Disabil Res. 2010;54:204-15. 
 https://doi.org/10.1111/j.1365-2788.2010.01251.x
 5. Hurren BJ, Flack NAMS. Prader-Willi syndrome: a spectrum 
of anatomical and clinical features. Clin Anat. 2016;29:
590-605. https://doi: 10.1002/ca.22686
 6. Emerick JE, Vogt KS. Endocrine manifestation and manage-
ment of Prader-Willi syndrome. Int J Pediatr Endocrinol. 
2013;1:14. https://doi.org/10.1186/1687-9856-2013-14
Gordana Stipančić et al. Prader-Willi syndrome and growth hormone
Acta Clin Croat, Vol. 57, No. 4, 2018 753
 7. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi 
syndrome. Genet Med. 2012;14(1):10-26. 
 https://doi.org/10.1038/gim.0b013e31822bead0
 8. Butler MG, Manzardo AM, Forster JL. Prader-Willi syn-
drome: clinical genetics and diagnostic aspects with treatment 
approaches. Curr Pediatr Rev. 2016;12(2):136-66. https://doi.
org/10.2174/1573396312666151123115250
 9. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer 
H. Population prevalence and estimated birth incidence and 
mortality rate for people with Prader-Willi syndrome in one 
UK Health Region. J Med Genet. 2001;38:792-8. https://doi.
org/10.1136/jmg38.11.792
10. Bridges N. What is the value of growth hormone therapy in 
Prader Willi syndrome. Arch Dis Child. 2014;99:166-70. 
https://doi.org/10.1136/archdischild-2013-303760
11. Wollmann HA, Schultz U, Grauer M, Ranke MB. Reference 
values for height and weight in Prader Willi syndrome based 
on 315 patients. Eur J Pediatr. 1998;157:634-42. http://dx.doi.
org/10.1007/s004310050901
12. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christian-
sen JS. Growth Hormone Research Society Workshop sum-
mary: Consensus guidelines for recombinant human growth 
hormone therapy in Prader-Willi syndrome. J Clin Endorinol 
Metab. 2013;98(6):E1072-87. 
 https://doi.org/10.1210/jc.2012-3888
13. Carrel A, Allen D, Myers S, Whitman B. Growth hormone 
improves body composition, fat utilization, physical strength 
and agility, and growth in Prader-Willi syndrome: a controlled 
study. J Pediatr. 1999 Feb;134(2):215-21. 
 https://doi.org/10.1016/s0022-3476(99)70418-x
14. Ritzen EM, Lindgren AC, Hagenas L, Marcus C, Muller J, 
Blichfeldt S, Swedish Growth Hormone Advisory Group. 
Growth hormone treatment of patients with Prader-Willi 




15. CDC, National Center for Health Statistics, Department of 
Health and Human Services. 2000 CDC Growth Charts for 
United States: Methods and Development. Vital and Health 
Statistics, Series 11, Number 246, May 2002. https://www.cdc.
gov/growthcharts/cdc_charts.htm
16. Tanner JM, Whitehouse RH. Clinical longitudinal standards 
for height, weight, height velocity, weight velocity and stages of 
puberty. Arch Dis Child. 1976;51:170-9. 
 http://dx.doi.org/10.1136/adc.51.3.170
17. Miller JL, Lynn CH, Shuster J, Driscoll DJ. A reduced-energy 
intake, well-balanced diet improves weight control in children 
with Prader-Willi syndrome. J Hum Nutr Diet. 2013;26:2-9. 
https://doi.org/10.1111/j.1365-277x.2012.01275.x
18. Bakker NE, Kuppens RJ, Siemensma EPC, Tummers-de Lind 
van Wijngaarden RFA, Festen DAM, Bindels-de Heus GCB, 
et al. Eight years of growth hormone treatment in children with 
Prader-Willi syndrome: maintaining the positive eff ects. J Clin 
Endocrinol Metab. 2013;98:4013-22. https://doi.org/10.1210/
jc.2013-2012
19. Meinhardt U, Christiansen JS, Farholt S, Lammer C, Oster-
gaard JR, Schmidt F, et al. Th e effi  cacy and safety of long-term 
Norditropin treatment in children with Prader-Willi syn-
drome. Horm Metab Res. 2013;45:532-6. https://doi.org/ 
10.1055/s-0033-1343449
20. Carrel AL, Myers SE, Whitman BY, Eickhoff  J, Allen DB. 
Long-term growth hormone therapy changes the natural his-
tory of body composition and motor function in children with 
Prader-Willi syndrome. J Clin Endocrinol Metab. 2010;95:
1131-6. https://doi.org/ 10.1210/jc.2009-1389
21. de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Ot-
ten BJ, van Mil EG, Rotteveel J, et al. Effi  cacy and safety of 
long-term continuous growth hormone treatment in children 
with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009 
Nov;94(11):4205-15. https://doi.org/10.1210/jc.2007-2294
22. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit 
JM, et al. Mental and motor development before and during 
growth hormone treatment in infants and toddlers with Prad-
er-Willi syndrome. Clin Endocrinol. 2008;68(6):919-25.
 http://dx.doi.org/10.1111/j.1365-2265.2007.03126.x
23. Angulo MA, Castro-Magana M, Lamerson M, Arquello R, 
Accacha S, Khan A. Final adult height in children with Prader 
Willi syndrome with and without human growth hormone 
treatment. Am J Med Genet. 2007;143A:1456-61. 
 https://doi.org/10.1002/ajmg.a.31824
24. Tanaka Y, Abe Y, Oto Y, Itabashi H, Shiraishi M, Yoshino A, et 
al. Characterization of fat distribution in Prader-Willi syn-
drome: relationship with adipocytokines and infl uence of 
growth hormone treatment. Am J Med Genet Part A. 2013;
161:27-33. https://doi.org/10.1002/ajmg.a.35653
25. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen 
DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ, et al. 
Benefi cial eff ects of growth hormone treatment on cognition in 
children with Prader-Willi syndrome: a randomized controlled 
trial and longitudinal study. J Clin Endocrinol Metab. 2012;
97(7):2307-14. https://doi.org/10.1210/jc.2011-1954
26. Myers SE, Whitman BY, Carrel AL, Moecher V, Bekx MT, 
Allan DB. Two years of growth hormone therapy in young 
children with Prader-Willi syndrome: physical and neuro-
developmental benefi ts. Am J Med Genet Part A. 2007;143
(5):443-8. DOI: 10.1002/ajmg.a.31468
27. Nugnes R, Zito E, Mozzillo E, Camarca ME, Riccio MP, Ter-
rone G, et al. Good cognitive performance in a child with Prad-
er-Willi syndrome. Int J Pediatr Endocrinol. 2013;1:14. https://
doi.org/10.1186/1824-7288-39-74.
28. Wolfgram PM, Carrel AL, Allen DB. Long-term eff ects of re-
combinant human growth hormone therapy in children with 
Prader-Willi syndrome. Curr Opin Pediatr. 2013;25(4):
509-14. https://doi.org/10.1097/MOP.0b013e328362c7a2
29. Einholzer U, Nordmann Y, L’Allemand D. Fatal outcome of 
sleep apnea in PWS during the initial phase of growth hor-
Gordana Stipančić et al. Prader-Willi syndrome and growth hormone
754 Acta Clin Croat, Vol. 57, No. 4, 2018
mone treatment. A case report. Horm Res. 2002;58(Suppl 3):
24-6. https://doi.org/10.1159/000066478
30. Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases 
of death in children with Prader-Willi syndrome (PWS). Am J 
Med Genet Part A. 2008;146A:881-7. 
 https://doi.org/10.1002/ajmg.a.32131
31. Whitman BY, Myers SE. Prader-Willi syndrome and growth 
hormone therapy: take a deep breath and weigh the data. J Pe-
diatr. 2013;162:224-6. https://doi.org/10.1136/jmg.38.11.792
32. Festen DA, de Weerd AW, van den Bossche RA, Joosten K, 
Hoeve H, Hokken-Koelege ACS. Sleep-related breathing dis-
order in prepubertal children with Prader-Willi syndrome and 
the eff ects of growth hormone treatment. J Clin Endocrinol 
Metab. 2006;91:4911-5. https://doi.org/10.1210/jc.2006-0765
33. Miller JL, Silverstein JH, Shuster J, Driscol DJ, Wagner M. 
Short-term eff ects of growth hormone on sleep abnormalities 
in Prader-Willi syndrome. J Clin Endocrinol Metab. 2006;
91:4911-5. http://dx.doi.org/10.1210/jc.2005-1279
34. Al-Saleh S, Al-Naimi A, Hamilton J, Zweerink A, Iaboni A, 
Narang I. Longitudinal evaluation of sleep-disordered breath-
ing in children with Prader-Willi syndrome during 2 years of 
growth hormone therapy. J Pediatr. 2013 Feb;162(2):263-8. 
https://doi.org/10.1016/j.jpeds.2012.07.042
35. Berini J, Spica Russotto V, Castelnuovo P, Di Candia S, Gar-
gantini L, Grugni G, et al.; Genetic Obesity Study Group of 
the Italian Society of Pediatric Endocrinology and Diabetolo-
gy (ISPED). Growth hormone therapy and respiratory disor-
ders: long-term follow-up in PWS children. J Clin Endocrinol 
Matab. 2013;98(9):E1516-23. 
 https://doi.org/10.1210/jc.2013-1831.
36. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syn-
drome: a review of clinical, genetic and endocrine fi ndings. J 
Endocrinol Invest. 2015;38:1249-63. 
 https://doi.org/10.1007/s40618-015-0312-9
37. Feigerlová E, Diene G, Oliver I, Gennero I, Salles JP, Arnaud 
C, et al. Elevated insulin-like growth factor-1 values in children 
with Prader-Willi syndrome compared with growth hormone 
(GH) defi ciency children over two years of GH treatment. J 
Clin Endocrinol Metab. 2010;95:4600-8. 
 https://doi.org./10.1210/jc.2009-1831
38. Bakker NE, van Doorn J, Renes JS, Donker GH, Hokken-
Koelega AC. IGF-1 levels, complex formation, and IGF bio-
activity in growth hormone-treated children with Prader-Willi 
syndrome. J Clin Endocrinol Metab. 2015;100(8):3041-9. 
https://doi.org/10.1210/jc.2015-1410
39. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de 
Jang FH, Hokken-Koelega AC. Testicular failure in boys with 
Prader-Willi syndrome: longitudinal studies of reproductive 
hormones. J Clin Endocrinol Metab. 2012;97(3):E452-9. 
https://doi.org/10.1210/jc.2011-1954
40. Coupaye M, Lorenzini F, Lloret-Linares C, Molinas C, Pinto 
G, Diene G, et al. Growth hormone therapy for children and 
adolescents with Prader-Willi syndrome is associated with 
 improved body composition and metabolic status in adulthood. 
J Clin Endocrinol Metab. 2013;98(2):E328-35. 
 https://doi.org/10.1210/jc.2012-2881
41. Sanchez-Ortiga R, Klibanski A, Tritos NA. Eff ects of recom-
binant human growth hormone therapy in adults with Prader-
Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf ). 2012 
Jul;77(1):86-93. 
 https://doi.org/10.1111/j.1365-2265.2011.04303.x
Gordana Stipančić et al. Prader-Willi syndrome and growth hormone
Acta Clin Croat, Vol. 57, No. 4, 2018 755
Sažetak
UČINAK TERAPIJE HORMONOM RASTA U DJECE S PRADER-WILLIJEVIM SINDROMOM 
– PRVA VLASTITA ISKUSTVA
G. Stipančić, M. Požgaj Šepec i L. La Grasta Sabolić
Prader-Willijev sindrom (PWS) najčešći je uzrok teške debljine u dječjoj dobi. Posljedica je izostanka ekspresije očevih 
gena u regiji 15q11.2-q13. Kliničkom slikom dominira hiperfagija, debljina, nizak rast, psihomotoričko zaostajanje i pore-
mećaji ponašanja. Terapija rekombinantnim humanim HR (rhHR) postala je, uz ograničenje energetskog unosa, imperativ u 
zbrinjavanju bolesnika s PWS-om. U 4 djece s PWS-om koja su ³2 godine liječena rhHR u dozi do 1 mg/m2/dan pratili smo 
antropometrijske parametre, tjelesnu visinu (TV) i indeks tjelesne mase (ITM) te učinak terapije na metabolizam ugljiko-
hidrata, lipida i pojavu neželjenih učinaka. Uz primjenu rhHR je TV standard deviation score (SDS) bio u porastu u odnosu 
na početnu vrijednost i nakon ³2 godine liječenja bio je unutar referentnog raspona za opću dječju populaciju. ITM SDS 
snizio se nakon prve godine liječenja, potom je bio u porastu, ali je i nadalje razina bila bolja nego u većine djece u popu laciji 
s PWS-om. Terapija rhHR-om nije nepovoljno utjecala na metabolizam glukoze i lipida te nije izazvala neželjenih učinaka. 
Terapija koja uključuje prehranu prilagođenu PWS-u i rhHR-om osigurala je zadovoljavajući rast djece i spriječila razvoj 
teške debljine bez neželjenih učinaka. Takav pristup liječenju osigurat će tranziciju većeg broja bolesnika u internističku skrb 
koja treba nastaviti s multidisciplinarnim pristupom u liječenju i skrbi za ovu skupinu bolesnika.
Ključne riječi: Prader-Willijev sindrom; Pretilost, morbidna; Humani hormon rasta – terapijska primjena; Paternalno naslje-
đivanje; Energetski unos
